Ensoma Secures $50 million in Series B Funding Round.
The funds will be used to advance Ensoma's Engenious in vivo engineered cell therapy platform and pipeline of genomic medicines for immuno-oncology and genetic diseases.
Funding Round Info:
Ensoma, a Boston-based genomic medicines company, has closed an extension of its Series B financing, raising an additional $50 million. This brings the total size of the funding round to an impressive final $135 million. The funds will be used to advance Ensoma's Engenious in vivo engineered cell therapy platform and pipeline of genomic medicines for immuno-oncology, genetic diseases, and other therapeutic applications. Investors in the funding round include 5AM Ventures, Arix Bioscience plc, AlexandriaVentureInvestments, the Bill & Melinda Gates Foundation, Kite Pharma, Bioluminescence Ventures, DELOS, Symbiosis Pharmaceutical Services, and Takeda Ventures, Inc..
About Ensoma:
Ensoma's mission is to create a new therapeutic category that addresses diseases such as cancer and autoimmunity. The company's innovative approach has the potential to revolutionize indications such as hemoglobinopathies and broaden patient eligibility through portable in vivo solutions.
The Executive Team:
Position: CEO & Board Member
Career Highlights:
CEO & Chairman at BlueRock Therapeutics
Ex Officio at Alliance for Regenerative Medicine
Founder, Vice Chairman of the Board at Invenra
President & COO at FUJIFILM Cellular Dynamics
Education:
University of Madison-Wisconsin
PhD, Molecular Toxicology
Environmental Toxicology Center and Department of Oncology. Mechanism of action of the chemotherapeutic agent tamoxifen and other triphenylethylene antiestrogens. Mechanisms of multistage carcinogenesis in rat liver. In vivo and in vitro toxicology experiments.
University of Delaware
Bachelor’s Degree in Biological Sciences
Major in Biology with a minor in Chemistry. Founder of Sigma Chi chapter at UD.
Position: CTO
Career Highlights:
CTO at 5AM Ventures 4:59 Newco
Senior VP, CMC Operations at Flexion Therapeutics
Director of Pharmaceutical Development at Merck Serono
Process Science Group Leader at Alkermes, Inc.
The Wharton School
MSE, Technology Management
Syracuse University
BS, Chemical Engineering
Position: Chief Business Officer
Career Highlights:
Chief of Staff to the CEO at Intellia Therapeutics, Inc.
Business Development at Shire Pharmaceuticals
Director of Corporate Relations at Healthcare Businesswomen’s Association
Education:
University of North Carolina at Chapel Hill
Ph.D., Cell and Developmental Biology
Thesis: "Retinoid and Serotonergic Signaling at Sites of Epithelial-Mesenchymal Interaction" resulted in five peer-reviewed publications.
University of Illinois Urbana-Champaign
B.S., Cell and Structural Biology
Min Wang Ph.D., J.D.
Position: President & COO
Career Highlights:
COO at Nested Therapeutics
COO at Monte Rosa Therapeutics
COO at BlueRock Therapeutics
SVP, General Counsel at Agios
Education:
Brown University
Ph.D., Organic Chemistry
Fordham University School of Law
Doctor of Law
Position: Chief Scientific Officer
Career Highlights:
Chief Scientific Officer at 5AM Ventures 4:59 NewCo
Rare Blood Disorders Therapeutic Area Head, Research at Sanofi
Senior VP, Research at Bioverativ
VP, Hematology Research at Biogen Idec
Education:
Harvard University
Ph.D., Biochemistry and Molecular Biology
Cornell University
B.S., Agricultural and Biological Engineering